External quality assessment for EGFR exon 20 mutation testing in patients with non-small cell lung cancer in Spain
The variability in the genotyping methods and the success rate obtained in our study highlight the importance of EQA in Spain to ensure high performance.
Authors
- Teresa Hernández‐Iglesias
- Yolanda Ruano (ORCID: https://orcid.org/0000-0001-6116-9369)
- Michele Biscuola (ORCID: https://orcid.org/0000-0003-4258-6161)
- Lourdes Gómez‐Gómez (ORCID: https://orcid.org/0000-0003-2586-4457)
- José Luis Rodríguez‐Peralto (ORCID: https://orcid.org/0000-0002-6578-7153)
- Santiago Ramón y Cajal (ORCID: https://orcid.org/0000-0002-3867-1390)
- Antonio Martínez
- Ana B. Enguita
Institutions
- Research Institute Hospital 12 de Octubre (ES)
- Sociedad Española de Medicina Interna (ES)
- Hospital Universitario 12 De Octubre (ES)
- Sociedad Española de Nefrología (ES)
- Hospital Clínic de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Instituto de Biomedicina de Sevilla (ES)
- Hospital Universitario Virgen del Rocío (ES)
Publication Details
- Journal
- Revista Española de Patología
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1016/j.patol.2025.100824
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00